Neurodegeneration is the progressive loss of structure and function in neurons, ending in their death, at a rate the nervous system cannot repair or compensate for. It is a process, not a single diagnosis. Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, Lewy body disease and ALS are all neurodegenerative; they differ mainly in which neurons fail first and which misfolded protein accumulates, and therefore in which symptoms appear. Because adult humans replace almost no neurons, the losses are largely one-way, which is why prevention aims at slowing the rate rather than restoring what is gone. The reference entry on Neurodegeneration covers the mechanisms in more depth.
What it measures
No single test returns a neurodegeneration score. Clinicians triangulate from three kinds of evidence. Structural imaging, usually MRI, shows atrophy: shrinkage of the hippocampus and cortex and widening of the fluid-filled ventricles, read against what is expected at a person’s age. Molecular scans can add where metabolism has dropped or where amyloid and tau deposits sit.
Fluid biomarkers are the fast-moving second strand. Neurofilament light chain, a structural protein released when axons are damaged, rises in blood and cerebrospinal fluid across many neurodegenerative diseases; it flags neuronal injury rather than naming a disease. Amyloid and phosphorylated tau assays index Alzheimer’s-type pathology specifically. Cut-offs differ by assay, platform and laboratory, and the healthy range shifts with age and kidney function, so a result means something only against the reporting lab’s own reference set. The third strand is function tracked over time: cognitive testing, gait and motor examination, everyday capability. The slope across repeated assessments carries more information than any single score.
Why it matters for longevity
Neurodegenerative disease is a main reason late-life years are lived dependent rather than independent, and dementia now ranks among the leading causes of death in older adults across high-income countries. For anyone thinking in healthspan rather than lifespan, this is the decisive organ.
The biology overlaps heavily with the rest of aging: misfolded proteins aggregate, mitochondria make less energy and more oxidative stress, waste clearance and autophagy slow, vascular damage accumulates, and the brain’s resident immune cells shift into a chronically activated state — Neuroinflammation — which accompanies most neurodegenerative processes, though whether it acts as cause, consequence or both differs by disease. That overlap is why midlife blood pressure, glucose control, smoking, hearing loss, inactivity and social isolation are all associated with later dementia risk in large cohorts. Those are observational associations, and the expert estimates of how much dementia is potentially preventable rest on the same observational base. One further finding shapes how all of it reads: two brains with the same visible pathology can produce very different symptoms, a gap usually described as Cognitive reserve.
What changes it
Nothing available today rebuilds lost neurons, so every lever acts on the rate, or on the risk of ever starting. Treating high blood pressure has the strongest randomized support: intensive lowering in a large trial reduced new cases of mild cognitive impairment, with a smaller and less certain effect on dementia itself. Regular aerobic and resistance exercise is consistently associated with lower risk and modestly improves cognitive test scores in trials, without being shown to prevent disease. A Mediterranean or MIND-style eating pattern tracks with slower cognitive decline in long cohorts; trial evidence is thinner and mixed. Treating hearing loss slowed decline in a randomized trial among older adults at higher risk, but not in the study population overall.
Sleep matters because clearance of waste protein from brain tissue is most active in deep sleep, and short or badly fragmented sleep tracks with worse cognitive outcomes. Not smoking, keeping alcohol low, staying socially and mentally engaged, and protecting your head from repeated injury belong on the same list. What you cannot change: chronological age, family history, and genotype, including the APOE variants that raise Alzheimer’s risk. Anti-amyloid antibodies modestly slow decline in early Alzheimer’s disease in trials, at the cost of real side effects and monitoring; they treat rather than prevent. Treat any supplement sold as reversing brain aging as unproven, because none has shown it.
Related reading
- How to Eat for Brain Health: A Cognitive Longevity Guide
- Mediterranean and MIND Diets Cut Dementia Risk
- Chronic Inflammation and Aging: Inflammaging
- Shingles Vaccine Linked to Lower Dementia Risk
Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.